1Abushulaih S, Ssad ED, Munsell M, et al. Incidence and severity of hand foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience [J]. Cancer Invest 2002,20(1):3-10. 被引量：1
1[1]Lokich JJ,Moore C. Chemotherapy-associated palmar-plantarerythrodysesthesia syndrome[J].Ann Intern Med,1984,101:798-799. 被引量：1
2[2]Curron CF,Luce JK. Fluorouracil and palmar-plantar erythro-dysesthesia[J]. Ann Intern Med,1989,111:858. 被引量：1
3[1]Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 1999, 17 (2):485 被引量：1
4[2]Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised,phase Ⅱ trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreatedwith anthracyclines. Br J Cancer, 2002, 86 (9):1367 被引量：1
5[3]Meta-analysis goup in cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced coleorectal cancer. J Clin Oneol. 1998, 16:301 被引量：1
6[4]Meta-analysis group in carcer. Toxicity of fiuorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol, 1998, 16:3537 被引量：1
7[5]Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Inter Med, 1984, 101 :798 被引量：1
8[6]Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 1999, 17 (2) :485 被引量：1
9[7]Vukelja SJ, Lombardo FA, James WD, et al. Pyridoxine for the palar-plantar erythrodysesthesia syndrome. Ann Inter Med,1989, 111:688 被引量：1
10[8]Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs, 1990, 8:57 被引量：1
